The recipe for success in the film industry is quite simple. All you need are supernatural characters (namely superheroes), a good cause, and an exceptional storyline.

The results of the much anticipated NOR-SWITCH study were released at the United European Gastroenterology (UEG) Week and show that patients can safely be switched from the originator infliximab Remicade® to the biosimilar infliximab (Remsima®).

Effective November 1, 2016, the ministry is enforcing generic substitution to the Exceptional Access Program (EAP).

The Quebec Association of Pharmacy Owners (AQPP) and the Quebec Health Minister Gaetan Barrette agreed to enter into negotiations to resolve the dispute around the professional allowances rule.

The proposed regulation around Bill 81 was published recently in the Official Gazette of Quebec.

As the price of medicines has become a global issue, the World Health Organization plans to develop over the course of the next year “a fair pricing model for pharmaceuticals”.

The review of Ontario’s MedsChecks is in. Changes are being mandated and the work is being standardized:

It was a busy spring with a number of pharmacy conferences back to back!

Inflectra® has been approved by Health Canada for the indications of Crohn's disease (CD), fistulising Crohn's disease and ulcerative colitis (UC). Inflectra now has all the indications first granted to the original biologic, Remicade®.

The Canadian Pharmaceutical market represents 2.2% of the global market. Canada does not have an explicit definition and regulatory pathway for rare disease drugs.